Cargando…

Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry

Background: Eosin-5-Maleimide (EMA)-based flow cytometry binds to red blood cell (RBC) membrane-associated proteins which can be used to detect red blood cell (RBC) membrane disorders. Myelodysplastic syndromes (MDS) are stem cell disorders resulting in ineffective hematopoiesis which is commonly pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Uman, Navavee, Kobbuaklee, Sirorat, Kansuwan, Patsita, Watanaboonyongcharoen, Phandee, Polprasert, Chantana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955372/
https://www.ncbi.nlm.nih.gov/pubmed/35323174
http://dx.doi.org/10.3390/hematolrep14010003
_version_ 1784676320402210816
author Uman, Navavee
Kobbuaklee, Sirorat
Kansuwan, Patsita
Watanaboonyongcharoen, Phandee
Polprasert, Chantana
author_facet Uman, Navavee
Kobbuaklee, Sirorat
Kansuwan, Patsita
Watanaboonyongcharoen, Phandee
Polprasert, Chantana
author_sort Uman, Navavee
collection PubMed
description Background: Eosin-5-Maleimide (EMA)-based flow cytometry binds to red blood cell (RBC) membrane-associated proteins which can be used to detect red blood cell (RBC) membrane disorders. Myelodysplastic syndromes (MDS) are stem cell disorders resulting in ineffective hematopoiesis which is commonly present with anemia and erythroid dysplasia. Objectives: We aimed to study RBC membrane defects in MDS using flow cytometry for EMA staining. Methods: We enrolled anemic patients who were diagnosed with low-risk MDS (R-IPSS score ≤ 3.5), RBC membrane disorders [hereditary spherocytosis (HS) and Southeast Asian ovalocytosis (SAO)], and normal controls. Complete blood count (CBC) and flow cytometry for EMA staining were performed. Results: There were 16 cases of low-risk MDS, 6 cases of RBC membrane disorders, and 15 control cases. Mean fluorescence intensity (MFI) of EMA binding test in the RBC membrane disorders was significantly lower than controls (17.6 vs. 24.3, p < 0.001), but the EMA binding test in the low-risk MDS was not significantly different than the controls (26.5 vs. 24.3, p = 0.08). Conclusion: the RBC membrane defect in low-risk MDS was not demonstrated as having detection ability using EMA binding test with flow cytometry.
format Online
Article
Text
id pubmed-8955372
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89553722022-03-26 Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry Uman, Navavee Kobbuaklee, Sirorat Kansuwan, Patsita Watanaboonyongcharoen, Phandee Polprasert, Chantana Hematol Rep Article Background: Eosin-5-Maleimide (EMA)-based flow cytometry binds to red blood cell (RBC) membrane-associated proteins which can be used to detect red blood cell (RBC) membrane disorders. Myelodysplastic syndromes (MDS) are stem cell disorders resulting in ineffective hematopoiesis which is commonly present with anemia and erythroid dysplasia. Objectives: We aimed to study RBC membrane defects in MDS using flow cytometry for EMA staining. Methods: We enrolled anemic patients who were diagnosed with low-risk MDS (R-IPSS score ≤ 3.5), RBC membrane disorders [hereditary spherocytosis (HS) and Southeast Asian ovalocytosis (SAO)], and normal controls. Complete blood count (CBC) and flow cytometry for EMA staining were performed. Results: There were 16 cases of low-risk MDS, 6 cases of RBC membrane disorders, and 15 control cases. Mean fluorescence intensity (MFI) of EMA binding test in the RBC membrane disorders was significantly lower than controls (17.6 vs. 24.3, p < 0.001), but the EMA binding test in the low-risk MDS was not significantly different than the controls (26.5 vs. 24.3, p = 0.08). Conclusion: the RBC membrane defect in low-risk MDS was not demonstrated as having detection ability using EMA binding test with flow cytometry. MDPI 2022-02-28 /pmc/articles/PMC8955372/ /pubmed/35323174 http://dx.doi.org/10.3390/hematolrep14010003 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Uman, Navavee
Kobbuaklee, Sirorat
Kansuwan, Patsita
Watanaboonyongcharoen, Phandee
Polprasert, Chantana
Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry
title Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry
title_full Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry
title_fullStr Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry
title_full_unstemmed Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry
title_short Detection of Red Blood Cell Membrane Proteins in Myelodysplastic Syndromes Using Eosin-5-Maleimide (EMA) Staining by Flow Cytometry
title_sort detection of red blood cell membrane proteins in myelodysplastic syndromes using eosin-5-maleimide (ema) staining by flow cytometry
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955372/
https://www.ncbi.nlm.nih.gov/pubmed/35323174
http://dx.doi.org/10.3390/hematolrep14010003
work_keys_str_mv AT umannavavee detectionofredbloodcellmembraneproteinsinmyelodysplasticsyndromesusingeosin5maleimideemastainingbyflowcytometry
AT kobbuakleesirorat detectionofredbloodcellmembraneproteinsinmyelodysplasticsyndromesusingeosin5maleimideemastainingbyflowcytometry
AT kansuwanpatsita detectionofredbloodcellmembraneproteinsinmyelodysplasticsyndromesusingeosin5maleimideemastainingbyflowcytometry
AT watanaboonyongcharoenphandee detectionofredbloodcellmembraneproteinsinmyelodysplasticsyndromesusingeosin5maleimideemastainingbyflowcytometry
AT polprasertchantana detectionofredbloodcellmembraneproteinsinmyelodysplasticsyndromesusingeosin5maleimideemastainingbyflowcytometry